Download citation file:
From Atlanta Veterans Affairs Medical Center, Decatur, Georgia, and Emory University School of Medicine, Atlanta, Georgia.
Acknowledgments: The authors thank the members of the Cardiopulmonary Resuscitation Committee of the Atlanta Veterans Affairs Medical Center.
Grant Support: By National Institutes of Health grant 1U01HL079156.
Potential Financial Conflicts of Interest: Grants received: A.M. Zafari (Cardiac Science).
Requests for Single Reprints: A. Maziar Zafari, MD, PhD, Division of Cardiology, Emory University, Woodruff Memorial Research Building, Room 322, 1639 Pierce Drive, Atlanta, GA 30322; e-mail, email@example.com.
Current Author Addresses: Dr. Ali: Veterans Affairs Medical Center Atlanta, Room 4A-168, 1670 Clairmont Road, Decatur, GA 30033.
Dr. Zafari: Division of Cardiology, Emory University, Woodruff Memorial Research Building, Room 322, 1639 Pierce Drive, Atlanta, GA 30322.
Sudden cardiac death is a major clinical problem, causing 300Â 000 to 400Â 000 deaths annually and 63% of all cardiac deaths. Despite the overall decrease in cardiovascular mortality, the proportion of cardiovascular death from sudden cardiac death has remained constant. Survival rates among patients who have out-of-hospital cardiac arrest vary from 5% to 18%, depending on the presenting rhythm.
The latest guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care published by the American Heart Association include substantial changes to the algorithms for basic life support and advanced cardiovascular life support. For unwitnessed cardiac arrest, immediate defibrillation of the patient is no longer recommended. Rather, 2 minutes of CPR before defibrillation is now recommended. People in cardiac arrest should no longer receive stacked shocks. The compressionâ€“ventilation ratio has been changed from 15:2 to 30:2.
This article is a contemporary review of the management of CPR and emergency cardiovascular care. It examines current practice and data supporting use of CPR, along with changes in the management of sudden cardiac death.
Please read the other comments before posting. Contributors must reveal any conflict
Comments are moderated and will appear on the site at the discretion of The American
College of Physicians editorial staff. Please be sure your email address is
updated in your account, otherwise the American College of Physicians will not be
able to contact you about your comment.
Anyone can submit a comment any time after publication, but only those submitted within 4 weeks of an article’s publication will be considered for print publication. One month after publication, editors review all posted comments and select some for publication in the Letters section of the print version of Annals. (Not peer reviewed)
Authors: No more than 5
Text: Word Limit 400 (excludes references), 5 references, no figures or tables
* = Required Field
Disclosure of Any Conflicts of Interest*
(applies to the past 5 years and foreseeable future) Indicate any potential conflicts
of interest of each author below, including specific financial interests and relationships
and affiliations relevant to the subject matter or materials discussed in the manuscript
(eg, employment/affiliation, grants or funding, consultancies, honoraria, speakers
bureau, stock ownership or options, expert testimony, royalties, donation of medical
equipment, or patents filed, received, or pending). If all authors have none, check
"No potential conflicts or relevant financial interests" in the box below. Please
also indicate any funding received in support of this work. The information will
be posted with your response.
Regarding the Narrative Review: Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: review of the Current Guidelines in the August 7, 2007 issue of the Annals of Internal Medicine, page 175 under the subheading "Atropine", it is stated that "Atropine is a cholinesterase inhibitor", however atropine is an acetylcholine receptor blocker (though it is used to treat cholinesterase inhibitor toxicity, e.g., from organophosphates) and thus acts as a parasympathetic inhibitor by that mechanism.
Ali and colleagues (1) review recent advances on cardiopulmonary resuscitation and emergency cardiovascular care. Though this is an excellent review of the most recent updates in resuscitation medicine, the authors ignored the latest therapeutic tool for the amelioration of neurological damage after cardiac arrest: therapeutic hypothermia. Based on overwhelming evidence from clinical trials, the American Heart Association incorporated therapeutic hypothermia into its Advanced Cardiac Life Support guidelines as the last link of the chain of survival (2). Recently, three trials demonstrated the neuroprotective effects of hypothermia after cardiac arrest. In the largest, the Hypothermia after cardiac Arrest (HACA) trial, 275 comatose survivors of ventricular fibrillation (VF) arrest were randomized to mild hypothermia to a target bladder temperature of 32-34 Â°C for 24 hours using a whole body blanket that delivered cooled air (3). A favorable outcome at six months, defined as independence with moderate-to-no disability, was seen in 55% of patients in the hypothermia group vs. 39% in the control group (relative risk 1.40; 95% CI, 1.08-1.81, P=0.009). Mortality was also reduced with hypothermia from 55% in the control group vs. 41% in hypothermia group (relative risk 0.74, 95%, CI, 0.58-0.85, p=0.02). In a second study, 75 comatose survivors of VF cardiac arrest were randomized to therapeutic hypothermia to a target pulmonary artery (PA) temperature of 33Â°C for 12 hrs using cold ice packs to the head and torso (4). A favorable neurological outcome occurred nearly twice as frequently in the hypothermia group (49% vs. 26%, p=0.046). In the third trial, 30 comatose survivors of primarily asystole and pulseless electrical activity (PEA) cardiac arrest were randomized to mild hypothermia to a target bladder temperature of 34 C? for a maximum of 4 hours using a helmet device placed around the head and neck which contained a solution of aqueous glycerol (5).The results of these three trials have been summarized in a recent meta-analysis (6). All three studies followed patients until death or hospital discharge. Patients in hypothermia group were more likely to be discharged with no or minimal neurological damage (RR, 1.68; 95% CI, 1.29-2.07) which translates into a number-needed to treat of 6 patients even when controlling for several variables such as age, gender, time from collapse to ROSC, and technique, the short term effect of hypothermia was maintained. As we know, morbidity and mortality of patients successfully resuscitated from cardiac arrest primarily depends on neurological outcome. Unfortunately, clinical trials of therapies directed towards reducing the extent of neuronal damage by means of pharmacologic interventions with barbiturates (7), calcium channel antagonists (8), benzodiazepines, magnesium, and steroids (9) have been discouraging. To date, the only clinically effective tool for amelioration of brain damage by ischemia and reperfusion is mild to moderate induced hypothermia. Nevertheless, for a variety of reasons, therapeutic hypothermia for cardiac arrest has been slow to catch on. In an a recently international internet- based survey to learn more about current practices and attitudes regarding hypothermia, the vast majority of cardiology and emergency medicine specialists (74% of US respondents) who care for cardiac arrest victims had never used hypothermia for this indication (10). The most frequently cited reasons for non-use by respondents were "not enough data," "not part of Advanced Cardiac Life Support guidelines," and "too technically difficult to use". All of these responses clearly contradict the current evidence. I agree that based on our better understanding of the pathophysiology of cardiac arrest and brain ischemia, clinicians must tailor their care to incorporate recent intra-cardiac arrest and post-cardiac arrest interventions aimed to improve neurological outcome and survival but we should not forget about the last link in the chain of survival. This is the only effective therapeutic tool for the amelioration of neurological damage after cardiac arrest.
Fred Rincon, MD Department of Neurology, Division of Neurocritical Care Columbia University College of Physicians and Surgeons, New York, NY 10034
1. Ali B, Zafari AM. Narrative Review: Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: Review of the Current Guidelines. Ann Intern Med. 2007;147:171-179.
2. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2005;112(24 Suppl):IV1-203.
3. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346(8):549-56.
4. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002;346(8):557-63.
5. Hachimi-Idrissi S, Corne L, Ebinger G, Michotte Y, Huyghens L. Mild hypothermia induced by a helmet device: a clinical feasibility study. Resuscitation. 2001;51(3):275-81.
6. Eisenburger P, Sterz F, Holzer M, et al. Therapeutic hypothermia after cardiac arrest. Curr Opin Crit Care. 2001;7(3):184-8.
7. Randomized clinical study of thiopental loading in comatose survivors of cardiac arrest. Brain Resuscitation Clinical Trial I Study Group. N Engl J Med. 1986;314(7):397-403.
8. A randomized clinical study of a calcium-entry blocker (lidoflazine) in the treatment of comatose survivors of cardiac arrest. Brain Resuscitation Clinical Trial II Study Group. N Engl J Med. 1991;324(18):1225-31.
9. Jastremski M, Sutton-Tyrrell K, Vaagenes P, Abramson N, Heiselman D, Safar P. Glucocorticoid treatment does not improve neurological recovery following cardiac arrest. Brain Resuscitation Clinical Trial I Study Group. Jama. 1989;262(24):3427-30.
10. Merchant RM, Soar J, Skrifvars MB, et al. Therapeutic hypothermia utilization among physicians after resuscitation from cardiac arrest. Crit Care Med. 2006;34(7):1935-40.
We thank Dr. Rincon for his comments about the role of induced hypothermia in the management of cardiac arrest. Our narrative review focused on the key modifications in the updated American Heart Association (AHA) guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care (ECC) to highlight the most important practical changes to CPR and ECC. (1) In all forms of cardiac arrest availability of high-quality basic life support skills has the highest impact on survival. Thus, the most critical determinant of survival from cardiac arrest is the presence of rescuers who are trained to push hard and fast allowing full chest recoil while minimizing interruptions in compressions, and defibrillating promptly when appropriate. (2)
Induced hypothermia has the potential to play a critical role in the postresuscitative care of a small subset of cardiac arrest victims. We concur with Dr. Rincon's comment that increased awareness about and induction of therapeutic hypothermia in select patients could translate into better outcomes with advanced cardiovascular life support. In the updated 2005 guidelines, the AHA identified induced hypothermia as one of several beneficial therapies in the postresuscitative care of cardiac arrest. (3) Benefit of induced hypothermia was observed in a select subset of patients who were initially comatose but hemodynamically stable after a witnessed arrest with ventricular fibrillation (VF). (3, 4) In the hypothermia after cardiac arrest (HACA) study only 8% of cardiac arrest victims were eligible to receive induced hypothermia. (4) Similar therapy may be beneficial for patients with non-VF arrest out of hospital or for in-hospital arrest. (3) Further experimental studies and clinical trials are required to determine optimal methods of cooling and optimal timing, duration, and intensity of cooling in order to achieve a measurable impact on CPR outcomes. (2, 5)
Finally, we would like to thank several readers, particularly Dr. Smith, for pointing out our error about the mechanism of action of atropine, an acetylcholine receptor antagonist of the muscarinic type.
1. Ali B, Zafari AM. Narrative review: cardiopulmonary resuscitation and emergency cardiovascular care: review of the current guidelines. Ann Intern Med 2007;147:171-179.
2. Hazinski MF, Nadkarni VM, Hickey RW, O'Connor R, Becker LB, Zaritsky A. Editorial: major changes in the 2005 AHA Guidelines for CPR and ECC: reaching the tipping point for change. Circulation 2005;112(suppl IV):IV- 206-IV-211.
3. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, Part 7.5: Postresuscitation Support. Circulation 2005;112(suppl IV):IV-84-IV-88.
4. The Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurological outcome after cardiac arrest. N Eng J Med 2002;346:549-556.
5. Safar PJ, Kochanek PM. Editorial: therapeutic hypothermia after cardiac arrest. N Eng J Med 2002;346:612-613.
The In the Clinic® slide sets are owned and copyrighted by the American College
of Physicians (ACP). All text, graphics, trademarks, and other intellectual property
incorporated into the slide sets remain the sole and exclusive property of the ACP.
The slide sets may be used only by the person who downloads or purchases them and
only for the purpose of presenting them during not-for-profit educational activities.
Users may incorporate the entire slide set or selected individual slides into their
own teaching presentations but may not alter the content of the slides in any way
or remove the ACP copyright notice. Users may make print copies for use as hand-outs
for the audience the user is personally addressing but may not otherwise reproduce
or distribute the slides by any means or media, including but not limited to sending
them as e-mail attachments, posting them on Internet or Intranet sites, publishing
them in meeting proceedings, or making them available for sale or distribution in
any unauthorized form, without the express written permission of the ACP. Unauthorized
use of the In the Clinic slide sets will constitute copyright infringement.
to gain full access to the content and tools.
Learn more about subscription options